Melissa Plets

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Sandip Pravin Patel, Megan Othus, Young Kwang Chae et al. · Clinical Cancer Research · 2020 · 326 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

Sumanta K. Pal, Catherine M. Tangen, Ian M. Thompson et al. · The Lancet · 2021 · 279 citations · Full text

Medicine, Oncology, Pharmacology +11

Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non–Muscle-Invasive Bladder Cancer on Tumor Recurrence

Edward M. Messing, Catherine M. Tangen, Seth P. Lerner et al. · JAMA · 2018 · 237 citations · Full text

Medicine, Oncology, Urology +17

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Megan Othus, Sandip Pravin Patel, Chris Ryan et al. · Journal for ImmunoTherapy of Cancer · 2021 · 159 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohort

Sandip Pravin Patel, Edward Mayerson, Young Kwang Chae et al. · Cancer · 2021 · 112 citations · Full text

Medicine, Oncology, Pharmacotherapy +17